Integrum Inc.

Integrum Inc., a foreign-owned, for-profit medical device manufacturer headquartered in San Francisco, California, supplies osseointegrated prosthetic implants, surgical instruments, and orthopedic rehabilitation equipment to the Department of Defense and Department of Veterans Affairs as a prime contractor exclusively on full-and-open procurements with no set-asides. The company is a subsidiary of Integrum AB and operates exclusively as a prime — all 50 recent awards are prime contracts or IDVs with no subcontract footprint. Integrum competes across NAICS 551512 (Surgical Appliance and Supplies Manufacturing) and PSC Medical And Surgical Instruments, Equipment, And Supplies, reflecting its focus on specialized prosthetic technology for military and veteran amputee rehabilitation.

Customer concentration is heavily skewed toward a single contracting engine. The Defense Health Agency accounts for 39 of 50 awards (78% of the prime portfolio) worth $17.6 million in combined potential value — effectively the entire revenue footprint. The Department of Veterans Affairs Veterans Integrated Service Networks 21 and 20 together place five additional awards worth $154 thousand and four worth $88 thousand respectively; the Department of the Navy Bureau of Medicine and Surgery has placed two awards worth $19 thousand. No other federal agencies appear in the source. The top-customers-by-count and top-customers-by-potential-value rankings are identical, indicating consistent dollar-per-award sizing across the portfolio.

Integrum's vehicle position rests on two single-award blanket purchase agreements. The primary vehicle is BPA HT001418A0005, a $6.5 million single-award BPA with the Defense Health Agency for main operating room surgical attachments, awarded June 12, 2023 and running through June 11, 2028 — this vehicle anchors 15 task orders worth $3.3 million in combined potential value. The second vehicle is BPA HT001423A0007, a smaller agreement carrying nine task orders worth $258 thousand. Integrum does not sit on any GWACs, governmentwide IDIQs, or GSA Schedules in the source data.

Recent activity shows decline. Awards per year have fallen from eleven in 2022 to nine in 2024 and five in 2025, with only one award recorded in 2026 to date. That downward trend, combined with minimal recompete exposure in the next twenty-four months (a single $19 thousand award completion), suggests mature, steady-state ordering from established customers rather than active growth or near-term recompete risk. Combined obligated dollars are $4.4 million against $17.9 million potential value, implying 25% cash-out to date and ongoing task-order execution against the core BPA vehicles.

Representative work includes a $92,600 purchase order from the Defense Health Agency in August 2023 for OPRA AXOR II devices (osseointegrated bone-conduction prosthetic implants), a $150 thousand firm fixed-price purchase order in August 2022 for an Integrum Transfemoral Amputation System, a $250 thousand BPA call in September 2021 for orthopedics and prosthetic supplies, and multiple smaller calls ranging from $9,999 to $86,079 for surgical implants, specialized application kits, and prosthetic rehabilitation equipment placed by the Defense Health Agency and VA VISNs 20 and 21. All awards are firm fixed-price with no set-aside designations.